A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors

Annals of Oncology

Volumn 11, Issue 3, 2000, Pages 333-338

  Tolcher, A W ^a   Aylesworth, C ^c   Rizzo, J ^a   Izbicka, E ^a   Campbell, E ^a   Kuhn, J ^b   Weiss, G ^b   Von Hoff, D D ^a   Rowinsky, E K ^a  

^a CTRC Institute for Drug Development   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Antimicrotubule; Cancer; Phase I; Rhizoxin

Indexed keywords

RHIZOXIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEIOMYOSARCOMA; MALE; MAXIMUM PERMISSIBLE DOSE; MELANOMA; MESOTHELIOMA; MICROTUBULE ASSEMBLY; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; LACTONES; MACROLIDES; MIDDLE AGED; NEOPLASMS; NEUTROPENIA;

EID: 0033996485     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008398725442     Document Type: Article

References (19)

1. Bai R, Pettit GR, Hamel E. Dolaslatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 1990; 39: 1941-9.
2. Takahashi M, Iwasaki S, Kobayashi H et al. Studies on macrocyclic lactone antibiotics. Xi. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues [published erratum appeared in J Antibiot (Tokyo) 1987; 40 (4): following 565]. J Antibiot 1987; 40: 66-72.
3. Tsuruo T, Oh-hara T, Iida H et al. Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res 1986; 46: 381-5.
4. Hendriks HR, Plowman J, Berger DP et al. Preclinical anti-tumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent [see comments]. Ann Oncol 1992; 3: 755-63.
5. Arioka H, Nishio K, Heike Y et al. In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance. J Cancer Res Clin Oncol 1997; 123: 195-200.
6. Bissett D, Graham MA, Setanoians A et al. Phase 1 and pharmacokinetic atudy of rhizoxin. Cancer Res 1992; 52: 2894-8.
7. McLeod HL, Murray LS, Wanders J et al. Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups. Br J Cancer 1996; 74: 1944-8.
8. Kaplan S, Hanauske AR, Pavlidis N et al. Single-agent activity of rhizoxin in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group. Br J Cancer 1996; 73: 403-5.
9. Verweij J, Wanders J, Gil T et al. Phase II study of rhizoxin in squamous-cell head and neck cancer. The EORTC Early Clinical Trials Group. Br J Cancer 1996; 73: 400-2.
10. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 461-3.
11. Von Hoff DD, Sandbach JF, Clark GM et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician [see comments]. J Natl Cancer Inst 1990; 82: 110-6.
12. Takadate A, Irikura M, Suehiro T et al. New labeling reagents for alcohols in fluorescence high-performance liquid chromatography. Chem Pharmacol Bull 1985; 33: 1164-9.
13. Toussaint C, Izzo J, Spielmann M et al. Phase I-II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 1994;12:2102-12.
14. Wilson WH, Berg SL, Bryant G et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I-II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-9.
15. Holmes FA, Valero V, Walters R et al. Phase III trial of paclitaxel (P) administered over 3- or 96-hour for melastatic breast cancer (MBC) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1996; 15: A91.
16. Fleming GF, Fasanmade A, Janisch L et al. Phase I clinical and pharmacokinetic study of rhizoxin (R) administered as a 72-hour (hr) continuous infusion (CIV) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997; 16: A833.
17. Akerley W, Glantz M, Choy H et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998; 16: 153-8.
18. Hainsworth JD, Burris HA 3rd, Erland JB et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 2164-8.
19. Fennelly D, Aghajanian C, Shapiro F et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187-92.